ARQ197 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cancer
Conditions
Liver Cancer
Trial Timeline
Jan 1, 2014 → Aug 1, 2017
NCT ID
NCT02029157About ARQ197 + Placebo
ARQ197 + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Liver Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02029157. Target conditions include Liver Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Liver Cancer were approved
Approved (9) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029157 | Phase 3 | Completed |
Competing Products
20 competing products in Liver Cancer